We are live on ! Find out more
RKDA icon

Arcadia Biosciences

21 hedge funds and large institutions have $6.54M invested in Arcadia Biosciences in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

0.06% more ownership

Funds ownership: 0.29%0.36% (+0.06%)

12% less capital invested

Capital invested by funds: $7.4M → $6.54M (-$858K)

22% less call options, than puts

Call options by funds: $619K | Put options by funds: $790K

22% less funds holding

Funds holding: 2721 (-6)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
21
Holders Change
-6
Holders Change %
-22.22%
% of All Funds
0.37%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
8
Reduced
4
Closed
8
Calls
$619K
Puts
$790K
Net Calls
-$171K
Net Calls Change
+$1.24M
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
-$1K -14 Closed
CG
27
Cutler Group
California
+$938 +10 New

RKDA Hedge Fund Activity: Q3 2021 in Review

21 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q3 2021, worth a combined $6.54M — down 12% from $7.4M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of RKDA and 2 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 8 added.

The largest buyer was Ardsley Advisory Partners, adding an estimated $1.23M. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $149K sold.

  • 21 institutional investors held Arcadia Biosciences (RKDA) as of Q3 2021, down from 27 in Q2 2021.
  • Funds reported $6.54M of Arcadia Biosciences stock for Q3 2021, down 12% quarter-over-quarter.
  • 2 funds opened new Arcadia Biosciences positions in Q3 2021 and 8 closed out, a net change of -6 holders.
  • The largest Arcadia Biosciences buyer in Q3 2021 was Ardsley Advisory Partners, an estimated $1.23M added.
  • The largest Arcadia Biosciences seller in Q3 2021 was Boothbay Fund Management, an estimated $149K sold.

Based on aggregated 13F filings for Q3 2021.